



Rybrevant in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

ONCOLOGY · EGFR EXON 20 NSCLC

The clinical situation

Rybrevant (amivantamab-vmjw) is an FDA-approved EGFR/MET bispecific antibody from Janssen for locally advanced or metastatic NSCLC carrying an EGFR exon 20 insertion mutation — a molecular subgroup that does not respond well to standard EGFR TKIs. Administered as IV infusion on a weighted schedule (weekly in first cycle, then every two weeks) in an outpatient oncology setting. Infusion-reaction premedication is standard per FDA labeling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms EGFR exon 20 insertion via NGS and documents a written rationale and line history.
- 2 Infusion facility confirmed.** A Saudi oncology day-unit with cold-chain storage and infusion-reaction management accepts the case.
- 3 SFDA named-patient application.** Clinical rationale, NGS molecular report, patient reference, product details, and chain-of-custody plan are filed with the SFDA Drug Sector.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; cold-chain shipment with temperature monitoring.
- 5 Arrival & first infusion.** The hospital pharmacy releases doses to the oncology day-unit with IV premedication protocols in place; subsequent cycles ship on a rolling basis.

Indicative economics

Reference US cash-pay range: USD 18,000–26,000 per cycle (first cycle typically higher due to split dose); drug-only reference. Reserve Meds provides a transparent delivered quote at intake.

Indicative first-dose timing

7–14 days from a complete SFDA application to first infusion, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review including molecular-diagnostic attestation. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through intake and subsequent cycles. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Rybrevant × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/rybrevant-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team